Contact lens manufacturer CooperVision is set to bring the innovative MiSight 1-day contact lenses (MiSight 1-day) for myopia management to patients in mainland China, distributed exclusively by EssilorLuxottica. MiSight 1-day is backed by extensive data gleaned from a seven-year clinical study for children and adolescents, and has been granted approval from the Chinese National Medical Products Administration (NMPA) for vision care – continued use of MiSight 1-day was reported to slow the change of optical axial length in patients, and the progression of myopia.
Professor Xingtao Zhou, Dean of the Eye and ENT Hospital of Fudan University, part of the esteemed attendees of a virtual product launch held earlier this month, remarked that the overall prevalence of myopia among Chinese children and adolescents in 2018, 2019, and 2020 was 53.6%, 50.2%, and 52.7%, respectively. In 2020, the myopia rate for students in primary school, middle school, and high school reached 35.6%, 71.1%, and 80.5%.
Representatives from CooperVision and EssilorLuxottica were joined by Professor Zhou and several other domestic and international ophthalmology and optometry luminaries at the launch event, including Dr. Juan Carlos Aragón, President of CooperVision Specialty EyeCare; Kok Leong Lim, President of the EssilorLuxottica Greater China Vision Care Division; and Professor Maria Liu from the University of California at Berkley.
The launch also saw certification for a pioneer group of MiSight 1-day fitters.
“CooperVision is dedicated to pioneering, innovative, and life-changing eye care technologies [and] are proud to launch this groundbreaking myopia management treatment for children and adolescents in China. In cooperation with EssilorLuxottica, China joins the family of more than 30 markets in which MiSight 1 day is being prescribed,” said Dr. Aragón.
“As a global leader in the design, manufacture, and distribution of ophthalmic lenses, frames, and sunglasses, EssilorLuxottica is committed to helping to eliminate uncorrected poor vision in a generation, in partnership with like-minded governments, NGOs, and other organisations – that includes myopia, an issue we’ve been striving to tackle by introducing total solutions to children and youth so as to help them slow down myopia progression and also reduce the risk of pathologies related to eyes,” concluded Lim.
MiSight 1 day will be available in all major cities in China. However, fitting and evaluation of the product should only be conducted in medical institutions by ophthalmologists, and patients monitored regularly when wearing MiSight 1 day.